ClinicaliQ Trial Snapshot
- First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy Adults — Recruiting • Phase I • NCT07646353.
- Early-stage trial testing a new antibody drug's safety and how the body processes it in healthy volunteers via injection or infusion.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study will assess the safety, tolerability, and pharmacokinetic properties of GSK4425689A monoclonal antibody (mAb) in healthy adults, when administered by either intravenous (IV) or subcutaneous (SC) routes. Conditions: Malaria, Falciparum Interventions: GSK4425689A SC, GSK4425689A IV, Placebo Lead Sponsor: GlaxoSmithKline Planned Enrollment: 40 participants